Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy.
Sherlock, SP; Palmer, J; Wagner, KR; Abdel-Hamid, HZ; Tian, C; Mah, JK; Muntoni, F; Guglieri, M; Butterfield, RJ; Charnas, L; et al.
Scientific Reports.
2022;
12.
P.12 A case report of near normalization of serum creatine phosphokinase in a patient with Duchenne muscular dystrophy during acute pancreatitis.
Zygmunt, A; Rybalsky, I; Reebals, L; Tian, C.
Neuromuscular Disorders.
2022;
32.
P.126 Genotype-unmatched controls are feasible for drug development in Duchenne muscular dystrophy (DMD).
Muntoni, F; Signorovitch, J; Frean, M; Fillbrunn, M; Sajeev, G; Ward, S; McDonald, C; Goemans, N; Niks, E; Wong, B; et al.
Neuromuscular Disorders.
2022;
32.
Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.
Sherlock, SP; Palmer, J; Wagner, KR; Abdel-Hamid, HZ; Bertini, E; Tian, C; Mah, JK; Kostera-Pruszczyk, A; Muntoni, F; Guglieri, M; et al.
Journal of Neurology.
2022;
269:4421-4435.
Obesity and loss of ambulation are associated with lower extremity oedema in Duchenne muscular dystrophy.
Freytag, JM; Ryan, TD; Bange, JE; Bonarrigo, KC; Chouteau, WA; Wittekind, SG; Tian, C; Gao, Z; Villa, CR.
Cardiology in the Young.
2022;
1-6.
Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls.
Muntoni, F; Signorovitch, J; Sajeev, G; Goemans, N; Wong, B; Tian, C; Mercuri, E; Done, N; Wong, H; Moss, J; et al.
Neuromuscular Disorders.
2022;
32:271-283.
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
McDonald, CM; Marbán, E; Hendrix, S; Hogan, N; Ruckdeschel Smith, R; Eagle, M; Finkel, RS; Tian, C; Janas, J; Harmelink, MM; et al.
The Lancet.
2022;
399:1049-1058.
The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
Nasomyont, N; Tian, C; Hornung, L; Khoury, J; Hochwalt, PM; Tilden, JC; Wong, BL; Rutter, MM.
Muscle and Nerve.
2021;
64:710-716.
Emergency Planning as Part of Healthcare Transition Preparation for Patients with Duchenne Muscular Dystrophy.
Chouteau, WA; Burrows, C; Wittekind, SG; Rutter, MM; Bange, JE; Sabla, GE; Rybalsky, I; Tian, C.
Journal of Pediatric Nursing.
2021;
61:298-304.
The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy.
Henson, SE; Lang, SM; Khoury, PR; Tian, C; Rutter, MM; Urbina, EM; Ryan, TD; Taylor, MD; Alsaied, T.
Journal of the American Heart Association.
2021;
10.